Piramal Pharma Announces Q2 & H1 FY26 Results; Concall on Nov 6, 2025
Piramal Pharma announced Q2 & H1 FY26 results with revenue at ₹ 2,044 Cr & ₹ 3,977 Cr respectively. EBITDA margins at 11% & 10%. Concall on Nov 6, 2025.
The results indicate a moderate impact due to decreased revenue and EBITDA, but the company is taking measures to improve performance.
The announcement presents both positive (debt reduction) and negative (revenue decrease) aspects of the company's performance.
* Piramal Pharma Limited announced its Q2 and H1 FY26 standalone and consolidated results, ended on 30th September 2025. * Revenue from Operations for Q2FY26 stood at ₹ 2,044 crore and ₹ 3,977 crore for H1FY26. * EBITDA margin for Q2FY26 was 11% and 10% for H1FY26. * Net Debt reduced by ₹ 228 crore to ₹ 3,971 crore at the end of H1FY26. * Released the 4th Annual Sustainability Report for FY25. * Nandini Piramal, Chairperson, noted the impact of inventory destocking and inconsistent biopharma funding on CDMO business, but sees a significant pick up in biopharma funding in September and October 2025. * The company will host an earnings conference call on 6th November 2025 from 9:30 AM to 10:15 AM (IST) to discuss the Q2 and H1 FY26 results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.